{
    "Pharmacology": {
        "Pharmacodynamics": {
            "Mechanism of action": [
                {
                    "1": "Serotonin Receptor Modulation in SSRI Treatment"
                },
                {
                    "7": "Impact of SSRIs on Neurogenesis"
                },
                {
                    "9": "SSRIs Effect on Neural Processing of Emotional Cues"
                },
                {
                    "53": "Neuroimaging of Serotonin Transporters"
                },
                {
                    "60": "SSRIs Effects on Ion Channels"
                },
                {
                    "63": "Methylenedioxymethamphetamine (MDMA) Induced Neurotoxicity"
                },
                {
                    "68": "SSRIs Effect on Pulmonary Hypertension"
                },
                {
                    "73": "Non-SERT Transporters in Antidepressant Action"
                },
                {
                    "76": "SERT Binding Mechanisms"
                },
                {
                    "77": "Astrocyte Receptors as a Target for SSRIs"
                },
                {
                    "84": "SSRIs Effect on Dopamine Receptors"
                },
                {
                    "85": "SSRIs Effects on Antimicrobials and Gut Microbiome"
                },
                {
                    "88": "Neurometabolite Changes with Antidepressants"
                },
                {
                    "89": "Galanin System in Antidepressant Action"
                },
                {
                    "92": "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients"
                }
            ],
            "Animal Models of Disorders": [
                {
                    "8": "The Chronic Unpredictable Mild Stress Model of Depression"
                },
                {
                    "12": "SSRIs in Forced Swimming Test"
                },
                {
                    "17": "SSRIs Effect on Fear"
                },
                {
                    "71": "Serotonergic Modulation of Cocaine Effects"
                }
            ],
            "Other": [
                {
                    "10": "Risk of Prenatal Exposure (Rodents)"
                },
                {
                    "93": "SSRIs in Model Organisms ( C. Elegans and Drosophilia)"
                }
            ]
        },
        "Pharmacokinetics": [
            {
                "6": "SSRIs and the Cytochrome P450 System"
            }
        ],
        "Pharmacogenetics": [
            {
                "20": "Serotonin Transporter Gene and Antidepressant Response"
            },
            {
                "72": "Pharmacogenetics in SSRI Treatment"
            }
        ],
        "Analytical Methods": [
            {
                "2": "Analytical Methods for SSRI Detection and Quantification"
            },
            {
                "27": "Paroxetine Binding to Serotonin Transporter"
            },
            {
                "55": "Synthetic Chemistry of Paroxetine"
            },
            {
                "64": "Laboratory Techniques for drug analysis"
            },
            {
                "91": "SSRI Crystal Structure and Complexation"
            }
        ],
        "Other Pharmacology": [
            {
                "15": "Inflammatory Biomarkers"
            },
            {
                "35": "Pharmacological Reviews"
            },
            {
                "70": "Antidepressant Drug Design"
            }
        ]
    },
    "Indications": {
        "Depressive Disorders": [
            {
                "5": "SSRIs for Pediatric Depression"
            },
            {
                "9": "SSRIs Effect on Neural Processing of Emotional Cues"
            },
            {
                "12": "SSRIs in Forced Swimming Test"
            },
            {
                "14": "Fluvoxamine for Depression"
            },
            {
                "19": "Escitalopram for Depression"
            },
            {
                "21": "Treatment Strategies and Outcomes in Depression"
            },
            {
                "23": "SSRIs for Depression in Patients with Cardiovascular Disease"
            },
            {
                "36": "SSRIs for Bipolar Depression"
            },
            {
                "41": "Venlafaxine vs SSRIs for Depression"
            },
            {
                "43": "SSRIs for Depression in Diabetes Patients"
            },
            {
                "47": "SSRIs for Depression with Cognitive Impairment"
            },
            {
                "58": "SSRIs for Depression in Parkinsons Patients"
            },
            {
                "59": "SSRIs for Depression in in Epileptic Patients"
            },
            {
                "61": "SSRIs and Augmentation for Treatment Resistant Depression"
            },
            {
                "74": "SSRIs for Depression, Comparative Effectiveness"
            },
            {
                "75": "SSRIs for Geriatric Depression"
            },
            {
                "79": "Agomelatin for Depression"
            },
            {
                "80": "Depression Treatment Guidelines"
            },
            {
                "81": "Sertraline for Depression"
            },
            {
                "86": "SSRIs for Depression after Traumatic Brain Injury"
            },
            {
                "92": "SSRIs Effect on Brain-derived Neurotrophic Factor (BDNF) Levels in Depressive Patients"
            },
            {
                "94": "SSRIs for Depression in Cancer Patients"
            },
            {
                "95": "SSRIs for Postpartum Depression"
            },
            {
                "96": "SSRIs Long-term Efficacy and Recurrent Depression"
            }
        ],
        "Anxiety": [
            {
                "17": "SSRIs Effect on Fear"
            },
            {
                "33": "SSRIs for Generalized Anxiety Disorder"
            },
            {
                "34": "SSRIs for Panic Disorder"
            },
            {
                "65": "SSRIs for Social Anxiety Disorder"
            }
        ],
        "OCD": [
            {
                "3": "SSRIs for OCD"
            },
            {
                "69": "SSRIs for Body Dysmorphic Disorder (BDD)"
            }
        ],
        "Weight and Eating Disorders": [
            {
                "26": "SSRIs for Weight Management"
            },
            {
                "57": "SSRIs for Eating Disorders"
            }
        ],
        "Substance Abuse/Addictions": [
            {
                "51": "SSRIs for Alcohol Dependence"
            },
            {
                "71": "Serotonergic Modulation of Cocaine Effects"
            }
        ],
        "Other": [
            {
                "11": "SSRIs for PTSD"
            },
            {
                "22": "SSRIs for Pain"
            },
            {
                "38": "Fluvoxamine for Covid 19"
            },
            {
                "40": "SSRIs Effect on Sleep"
            },
            {
                "44": "SSRIs for Menopausal Vasomotor Symptoms (Hot flashes)"
            },
            {
                "46": "Premature Ejaculation"
            },
            {
                "50": "SSRIs for Irritable Bowel Syndrome"
            },
            {
                "52": "SSRIs for Premenstrual Dysphoric Disorder (PMDD)"
            },
            {
                "54": "SSRIs for (Psycho)dermatological Diseases"
            },
            {
                "56": "SSRIs for Autism Spectrum Disorders"
            },
            {
                "67": "SSRIs (Fluvoxamine) for Schizophrenia"
            },
            {
                "68": "SSRIs Effect on Pulmonary Hypertension"
            },
            {
                "78": "SSRIs for Borderline Personality Disorder"
            },
            {
                "87": "Antifungal Activity of Sertraline"
            },
            {
                "90": "SSRIs for Fibromyalgia"
            }
        ]
    },
    "Safety": {
        "Special Populations": {
            "Pediatrics": [
                {
                    "5": "SSRIs for Pediatric Depression"
                },
                {
                    "31": "Suicice Risk"
                }
            ],
            "Geriatrics": [
                {
                    "18": "Post-Stroke SSRI Use"
                },
                {
                    "23": "SSRIs for Depression in Patients with Cardiovascular Disease"
                },
                {
                    "24": "SSRIs in Dementias"
                },
                {
                    "47": "SSRIs for Depression with Cognitive Impairment"
                },
                {
                    "58": "SSRIs for Depression in Parkinsons Patients"
                },
                {
                    "75": "SSRIs for Geriatric Depression"
                }
            ],
            "Other": [
                {
                    "43": "SSRIs for Depression in Diabetes Patients"
                },
                {
                    "59": "SSRIs for Depression in in Epileptic Patients"
                },
                {
                    "86": "SSRIs for Depression after Traumatic Brain Injury"
                },
                {
                    "94": "SSRIs for Depression in Cancer Patients"
                }
            ]
        },
        "Perinatal Exposure": [
            {
                "4": "Risk of Prenatal Exposure"
            },
            {
                "10": "Risk of Prenatal Exposure (Rodents)"
            },
            {
                "42": "SSRI Effects on Lactation"
            },
            {
                "95": "SSRIs for Postpartum Depression"
            }
        ],
        "Other": [
            {
                "16": "Sexual Dysfunction"
            },
            {
                "25": "Serotonin Syndrome"
            },
            {
                "28": "Bleeding Risk"
            },
            {
                "30": "Oncopreventive and Oncolytic Properties of SSRIs"
            },
            {
                "31": "Suicice Risk"
            },
            {
                "32": "Fracture Risk"
            },
            {
                "37": "Hepatotoxic Risk"
            },
            {
                "45": "Pharmacovigilance of SSRIs"
            },
            {
                "48": "QTC Prolongation"
            },
            {
                "49": "Extrapyramidal Reactions Risk"
            },
            {
                "66": "Forensic Toxicology of Fatal Overdoses"
            },
            {
                "82": "Withdrawal Symptoms"
            },
            {
                "83": "Hyponatremia Risk"
            },
            {
                "99": "SRRIs and Ocular Safety"
            }
        ]
    },
    "Other": {
        "Ecotoxicology": [
            {
                "0": "Aquatic Ecotoxicology"
            },
            {
                "62": "Environmental Degradation of Antidepressants"
            }
        ],
        "Other": [
            {
                "13": "SSRI Utilization Patterns"
            },
            {
                "29": "Antidepressant-like Effects of Herbal Extracts in Animal Models"
            },
            {
                "39": "Pharmacoeconomics of SSRIs for Depression"
            },
            {
                "97": "Canine Behavioral Disorders"
            }
        ]
    }
}